dc.contributor.author |
Perez-Zsolt, Daniel |
dc.contributor.author |
Cantero, Jon |
dc.contributor.author |
Erkizia, Itziar |
dc.contributor.author |
Benet, Susana |
dc.contributor.author |
Pino, M. |
dc.contributor.author |
Serra-Peinado, Carla |
dc.contributor.author |
Hernández Gallego, Alba |
dc.contributor.author |
Castellvi, Josep |
dc.contributor.author |
Tapia, G. |
dc.contributor.author |
Arnau-Saz, V. |
dc.contributor.author |
Garrido, J. |
dc.contributor.author |
Tarrats, Antoni |
dc.contributor.author |
Buzón, Maria José |
dc.contributor.author |
Martinez-Picado, J. |
dc.contributor.author |
Izquierdo Useros, Nuria |
dc.contributor.author |
Genescà Ferrer, Meritxell. |
dc.date |
2019 |
dc.identifier |
https://ddd.uab.cat/record/223637 |
dc.identifier |
urn:10.3389/fimmu.2019.00825 |
dc.identifier |
urn:oai:ddd.uab.cat:223637 |
dc.identifier |
urn:scopus_id:85066480905 |
dc.identifier |
urn:articleid:16643224v10p825 |
dc.identifier |
urn:oai:egreta.uab.cat:publications/4b97d0dc-aab9-4249-9133-1e2092b2e874 |
dc.identifier |
urn:pmid:31114569 |
dc.identifier |
urn:pmc-uid:6503733 |
dc.identifier |
urn:pmcid:PMC6503733 |
dc.identifier |
urn:oai:pubmedcentral.nih.gov:6503733 |
dc.format |
application/pdf |
dc.language |
eng |
dc.publisher |
|
dc.relation |
Ministerio de Economía y Competitividad BES-2014-069931 |
dc.relation |
Ministerio de Economía y Competitividad SAF2015-67334-R |
dc.relation |
Instituto de Salud Carlos III RD16/0025/0007 |
dc.relation |
Instituto de Salud Carlos III CP17/00179 |
dc.relation |
Instituto de Salud Carlos III PI14/01235 |
dc.relation |
Instituto de Salud Carlos III PI17/01470 |
dc.relation |
Frontiers in immunology ; Vol. 10 (april 2019), p. 825 |
dc.rights |
open access |
dc.rights |
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. |
dc.rights |
https://creativecommons.org/licenses/by/4.0/ |
dc.subject |
Cervix |
dc.subject |
Siglec-1 |
dc.subject |
HIV-1 |
dc.subject |
Trans-infection |
dc.subject |
Myeloid cells |
dc.title |
Dendritic Cells From the Cervical Mucosa Capture and Transfer HIV-1 via Siglec-1 |
dc.type |
Article |
dc.description.abstract |
Altres ajuts: JM-P and NI-U are supported by the Spanish Secretariat of State of Research, Development and Innovation through grant SAF2016-80033-R. MG is supported by a Marie Curie Career Integration Grant (CIG) from the European Commission and by the Pla estratègic de recerca i innovació en salut (PERIS), from the Catalan government. |
dc.description.abstract |
Antigen presenting cells from the cervical mucosa are thought to amplify incoming HIV-1 and spread infection systemically without being productively infected. Yet, the molecular mechanism at the cervical mucosa underlying this viral transmission pathway remains unknown. Here we identified a subset of HLA-DR+ CD14+ CD11c+ cervical DCs at the lamina propria of the ectocervix and the endocervix that expressed the type-I interferon inducible lectin Siglec-1 (CD169), which promoted viral uptake. In the cervical biopsy of a viremic HIV-1+ patient, Siglec-1+ cells harbored HIV-1-containing compartments, demonstrating that in vivo, these cells trap viruses. Ex vivo, a type-I interferon antiviral environment enhanced viral capture and trans-infection via Siglec-1. Nonetheless, HIV-1 transfer via cervical DCs was effectively prevented with antibodies against Siglec-1. Our findings contribute to decipher how cervical DCs may boost HIV-1 replication and promote systemic viral spread from the cervical mucosa, and highlight the importance of including inhibitors against Siglec-1 in microbicidal strategies. |